Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

A collaborative research group has uncovered a new mechanism in the growth of amyloid β (Aβ) fibrils, which are closely ...

Alzamend Neuro has determined the dosage of AL001, its lithium therapy for Alzheimer’s disease, that will be used in future ...

A retired cop in Michigan called dispatchers to report he gave his wife a “merciful ending” to her Alzheimer’s disease before ...

Research reveals advanced brain aging in older adults correlates with cognitive decline and Alzheimer's risk, highlighting ...

Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with ...

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may ...

Researchers have identified a key mechanism in the development of Alzheimer's disease involving the growth and pause of ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...